


Bioinspired Syntheses of the Pyridoacridine Marine Alkaloids Demethyldeoxyamphimedine, Deoxyamphimedine, and Amphimedine

Iman M. Khalil, David Barker, and Brent R. Copp*

School of Chemical Sciences, University of Auckland, 23 Symonds St, Auckland 1010, New Zealand

S Supporting Information



ABSTRACT: Efficient bioinspired syntheses of the biologically active pyridoacridine marine alkaloids demethyldeoxyamphimedine, deoxyamphimedine, and amphimedine are reported. Reaction of styelsamine D, prepared via an optimized route starting from Boc-dopamine, with paraformaldehyde afforded demethyldeoxyamphimedine and deoxyamphimedine. Oxidation of the latter using either $K_3[Fe(CN)_6]$ or DMSO/conc. HCl gave amphimedine in 8 steps from tryptamine with an overall yield of 14%. The versatility of the method was demonstrated by the synthesis of non-natural ethyl and benzyl congeners of deoxyamphimedine and amphimedine.

Amphimedine (1), reported in 1983 from an *Amphimedon* sp. sponge, was the first example of a natural product bearing a new alkaloid skeleton.¹ Related dopamine-based pyridoacridines, encapsulating the 11*H*-pyrido[4,3,2-*mn*]-acridine skeleton, now number greater than 40.^{2,3} Alkaloids belonging to this family typically exhibit significant biological activities, including cytotoxicity.⁴ For example, of the pentacyclic pyridoacridine analogues amphimedine (1), neoamphimedine (2),⁵ deoxyamphimedine (3),⁶ and demethyldeoxyamphimedine (4)⁷ (Figure 1), 1 induces specific developmental effects in zebrafish embryos,⁸ 2 is cytotoxic and stimulates topoisomerase II to catenate DNA,^{5,9,10} and 3 causes damage to DNA via the production of reactive oxygen species.¹¹ A number of syntheses of amphimedine (1)^{12–15} and demethyldeoxyamphimedine (4)^{16,17} have been reported, all relying upon either hetero-Diels–Alder or Pd- or Li-metalation reactions to construct the core skeleton. In the case of amphimedine, total syntheses have been reported that incorporate a longest linear sequence of up to 13 steps. Syntheses of demethyldeoxyamphimedine on the other hand are considerably shorter with the recent report by Bracher of a 4 step, 6.4% yield sequence being the most efficient to date.¹⁷ None of the syntheses, however, can be considered bioinspired or biomimetic. Several groups have speculated that styelsamine D (5), itself a natural product isolated from the ascidian *Eusynstyela latericius*,¹⁸ could be a biosynthetic intermediate to a large subset of pyridoacridine alkaloids, including 1–4.^{3,7} Preliminary experiments by Bry et al. observed that addition of formaldehyde to a marine organism extract that contains both styelsamine D (5) and demethyldeoxyamphimedine (4)





Figure 1. Structures of marine pyridoacridine alkaloids amphimedine (1), neoamphimedine (2), deoxyamphimedine (3), demethyldeoxyamphimedine (4), and styelsamine D (5).

led to the disappearance of the former with time and a concomitant increase in detectable quantities of the latter.⁷

Received: October 5, 2015

Published: December 7, 2015

Scheme 1. Synthesis of Demethyldeoxyamphimedine (4), Deoxyamphimedine (3), and Amphimedine (1)



We report herein an improved synthesis of styelsamine D, efficient bioinspired conversion of styelsamine D (5) to demethyldeoxyamphimedine (4) and deoxyamphimedine (3), and subsequent oxidation of the latter to amphimedine (1). The versatility of the approach is demonstrated by the synthesis of non-natural analogues of 1 and 3. In addition, an alternative route to amphimedine via the anticipated natural product *N*-methyl styelsamine D is also demonstrated.

Skyler and Heathcock have previously reported the development of a biomimetic synthesis of styelsamine B (*N*-acetyl styelsamine D), where oxidative coupling of *N*-acetyl dopamine with kynuramine followed by in situ acid-mediated ring closure led to the formation of the required pyridoacridine skeleton.¹⁹ This procedure required the product to undergo subsequent acid hydrolysis (MeOH/4 N HCl (1:1), 80 °C, 2 d) to afford styelsamine D (5).^{3,20} We have modified this reaction process to more specifically target the synthesis of styelsamine D by utilizing *tert*-butyl 2-(3,4-dihydroxyphenyl) ethylcarbamate (Boc-dopamine, 6) as starting material and by optimizing the synthesis of the coupling partner kynuramine (7). The modified synthesis of kynuramine (7) began by protection of tryptamine (8) to give carbamate 9 (Scheme 1). Oxidation of the protected tryptamine (9) yielded oxindole 10,²¹ which upon treatment with O₂ in basic conditions^{21,22} afforded protected kynuramine (11) in quantitative yield. Removal of the carbamate protecting group gave kynuramine (7) in 81% yield (Scheme 1). This synthetic route circumvents the use of ozone as the ring opening reagent and affords kynuramine with an improved overall yield of 67% (previous overall yield was 57%).¹⁹ With kynuramine in hand, coupling of 7 with 6²³ using a two-step sequence afforded styelsamine D (5) in 34% yield (Scheme 1). Reaction of 5 with paraformaldehyde (5 equiv) in acetic acid²⁴ gratifyingly afforded the two pentacyclic natural products deoxyamphimedine (3) in 48% yield and demethyldeoxyamphimedine (4) in 52% yield. Repeating our reaction with an increasing number of equivalents of paraformaldehyde gave a corresponding increase in the yield of 3 vs 4 (9.1 equiv, 58 and 34%, respectively; 15 equiv, 66 and 34%, respectively). This represents the first reported synthesis of deoxyamphimedine and the highest yielding synthesis of demethyldeoxyamphimedine reported to date.


With an optimized synthesis of styelsamine D and with the successful reaction with paraformaldehyde, our attention then

turned to oxidation of deoxyamphimedine. We were interested in not only achieving oxidation but also discerning whether one or both of amphimedine (1) or neoamphimedine (2) were the product(s). The reagent of choice for oxidation of a methylpyridinium to an *N*-methylpyridone is K₃[Fe(CN)₆] in aq NaOH.^{14,25,26} In the present study, oxidation of deoxyamphimedine 3 using alkaline ferricyanide yielded exclusively amphimedine (1) in 92% yield. A range of other oxidants were subsequently explored (data not shown), and it was found that the reaction of deoxyamphimedine (3) in DMSO/conc. HCl^{21,22} (9:1) afforded amphimedine in 75% yield in addition to trace amounts of demethylated starting material 4. Changing the relative ratio of DMSO/conc. HCl used in the reaction from 9:1 to 11:1 afforded demethyldeoxyamphimedine (4) in 14.5% yield and only trace amounts of amphimedine. This is the first apparent report of *N*-methylpyridone formation using such a mild oxidant system. Neither of these successful oxidants (K₃[Fe(CN)₆] or DMSO/conc. HCl) afforded detectable quantities of the isomeric neoamphimedine (2) natural product.

Among the pyridoacridine alkaloids, deoxyamphimedine (3) and ascididemin are unique in their ability to induce damage in DNA via the generation of reactive oxygen species,^{11,27} whereas amphimedine appears to be unique in inducing a specific but mechanistically undefined developmental phenotype in zebrafish.⁸ To facilitate future structure–activity relationship studies, we investigated whether our new methodology could be used to synthesize new non-natural ethyl and benzyl analogues of both deoxyamphimedine and amphimedine (Scheme 2).


Alkylation of *N*-(3,4-dimethoxyphenethyl)acetamide (12)²⁰ proceeded smoothly to give 13–15 (96–99%), which were then de-*O*-methylated (BBr₃, CH₂Cl₂) to give catechols 16–18 (61–99%). Subsequent oxidative coupling with kynuramine (7) afforded the alkylated styelsamine B analogues 19–21 (10–12%), which upon hydrolysis in aq HCl, gave the corresponding *N*-alkyl styelsamine D analogues 22–24 (51–71%). Ring closure of the anticipated natural product *N*-methylstyelsamine D (22)³ using paraformaldehyde in acetic acid afforded deoxyamphimedine (3) in 91% yield, and the reaction of ethyl (23) and benzyl (24) analogues of styelsamine D gave the corresponding deoxyamphimedine analogues 25 and 26 in good yields (83 and 91%, respectively).²⁸ Finally, oxidation of the latter two products using K₃[Fe(CN)₆]/NaOH

Scheme 2. Synthesis of Deoxyamphimedine Analogues 25 and 26 and Amphimedine Analogues 27 and 28



afforded the non-natural amphimedine analogues 27 (85% yield) and 28 (34% yield).

Scheme 3. Proposed Mechanism for the Conversion of Styelsamine D (5) to Demethyldeoxyamphimedine (4) and Deoxyamphimedine (3)



The observed conversion of styelsamine D (5) to both demethyldeoxyamphimedine and deoxyamphimedine suggests a mechanism whereby the first mole of formaldehyde achieves a Pictet–Spengler-type ring closure²⁹ to form 29 (Scheme 3). Pentacycle 29 can then either undergo in situ oxidation to demethyldeoxyamphimedine (4) or alternatively react with a second equivalent of formaldehyde to give 30 with subsequent tautomerization and oxidation affording deoxyamphimedine (3). Observation of elevated yields of 3, at the expense of 4, upon reaction of styelsamine D with increasing equivalents of paraformaldehyde provides support for this mechanism.

In summary, we have described a versatile bioinspired approach to the synthesis of the marine natural products demethyldeoxyamphimedine (4), deoxyamphimedine (3), and amphimedine (1) and used the methodology to prepare novel analogues. It is anticipated that this protocol will be useful for the synthesis of other structurally related biologically active pyridoacridine natural products.

EXPERIMENTAL SECTION

General Procedures. NMR spectra were recorded at either 500 or 400 MHz for ¹H nuclei and 125 or 100 MHz for ¹³C nuclei. Residual solvent signals or TMS (when present) were used as reference (CD₃OD: δ_H 3.31, δ_C 49.0; CDCl₃: δ_H TMS 0, δ_C 77.16; TFA-*d*/CDCl₃: δ_H TMS 0, δ_C 77.16; DMSO-*d*₆: δ_H 2.50, δ_C 39.52). Assignments were based on 2D NMR data using standard COSY, multiplicity edited HSQC, HMBC, and where appropriate NOESY pulse sequences. ESI-MS (including high resolution) data were acquired on a microTOF Q II mass spectrometer. Analytical reversed-phase HPLC was run using a C₈ column (3 μm, 7 × 33 mm) and eluted with a linear gradient of H₂O (0.05% TFA) to MeCN over 13.5 min at 2 mL/min. Reversed-phase flash column chromatography was carried out on C₂ (40–63 μm) or LH-20 solid support. Silica gel column chromatography was carried out on silica media with either 40–63 or 15–40 μm particle sizes. All solvents used were distilled at analytical grade or better. Chemical reagents used were purchased from standard chemical suppliers.

Tryptamine-Methyl Carbamate (9). A solution of tryptamine hydrochloride (15 g, 0.090 mol), EtOAc (150 mL), and NaOH (1 N, 95 mL) was degassed and stirred followed by dropwise addition of methyl chloroformate (11.5 g, 9.40 mL, 0.12 mol) under N₂ atmosphere. The mixture was stirred for 45 min at rt and then washed with water (2 × 50 mL) and dried (MgSO₄), and the solvent was removed under reduced pressure. The crude reaction product was then dissolved in EtOAc (10 mL) and added to *n*-hexane (100 mL) to yield 9 as a brown solid (20.4 g, quant.) after filtration. ¹H and ¹³C NMR data matched literature values.¹⁹

Oxindole (10). A solution of tryptamine methyl carbamate (9, 2.33 g, 10.7 mmol) in glacial acetic acid (50 mL) was added slowly to a solution of DMSO (2.1 mL) and concd HCl (10.7 mL) and stirred for 1 h and 15 min. The reaction was then poured into saturated aqueous Na₂CO₃ (180 mL) and extracted with EtOAc (3 × 80 mL). The

combined organic layers were washed with brine (180 mL) and dried (MgSO_4), and the solvent was removed in vacuo. Purification by silica gel column chromatography (*n*-hexane/EtOAc) gave oxindole **10** as a dark yellow oil (2.1 g, 83%). R_f (100% CH_2Cl_2) 0.15; (+)-HRESIMS m/z 235.1077 [$\text{M} + \text{H}$]⁺ (calcd for $\text{C}_{12}\text{H}_{13}\text{N}_2\text{O}_3$, 235.1077). ¹H and ¹³C NMR data matched literature values.²¹

Kynuramine-Methyl Carbamate (11). Oxygen was bubbled into a stirred solution of the oxindole **10** (0.2 g, 0.85 mmol) in 1 N NaOH (10 mL). The resulting mixture was stirred for a further 3 h and 45 min at rt after which 10% HCl was added to adjust the pH to 7. The mixture was then extracted with EtOAc (3 × 20 mL); the combined organic extracts were dried over MgSO_4 , and the solvent was removed under reduced pressure to yield **11** as a yellow solid (0.19 g, quant.). ¹H and ¹³C NMR data matched literature values.¹⁹

Kynuramine Dihydrobromide (7). A solution of **11** (0.19 g, 0.65 mmol) in HBr in acetic acid (7 mL) was stirred and heated at 80 °C under N_2 atmosphere overnight. After the solution was cooled to rt, THF was added (15 mL), and the mixture was stirred at 0 °C for 30 min. The brown solid was then triturated (THF) to yield **7** as an off-white solid (0.19 g, 81.1%). ¹H and ¹³C NMR data matched literature values.¹⁹

N-(3,4-Dimethoxyphenethyl)acetamide (12). A solution of 2-(3,4-dimethoxyphenyl)ethyl amine (0.2 g, 0.19 mL, 1.10 mmol) in Et_3N (0.24 mL, 0.20 g, 1.99 mmol) and acetic anhydride (0.38 mL, 0.41 g, 3.97 mmol) was stirred at rt under N_2 atmosphere for 45 min. Dichloromethane (5 mL) was then added, and the mixture was washed with H_2O (10 mL). The organic phase was then dried (MgSO_4), and the solvent was removed under reduced pressure to afford **12** as a dark yellow oil (0.24 g, 97.6%). ¹H and ¹³C NMR data matched literature values.²⁰

N-Boc-Dopamine (6). Boc_2O (1.09 g, 5.00 mmol) was added to a solution of dopamine hydrochloride (0.86 g, 4.53 mmol) in a mixture of THF (9.4 mL) and sat. aq NaHCO_3 (5.6 mL). The reaction mixture was stirred at rt for 2 h after which the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic extracts were washed with brine, dried over MgSO_4 , and concentrated under reduced pressure to yield **6** as a white solid (1.15 g, quant.). ¹H and ¹³C NMR data matched literature values.²³

Styelsamine D (5). Kynuramine dihydrobromide (**7**) (0.10 g, 0.41 mmol) was added to a stirred solution of *tert*-butyl 2-(3,4-dihydroxyphenyl)ethylcarbamate (**6**, 0.13 g, 0.39 mmol) in MeOH/acetic acid (2:1, 6 mL) under a N_2 atmosphere followed by the addition of $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$ (0.022 g, 0.054 mmol) and Ag_2O (0.20 g, 0.99 mmol). The mixture was stirred at 40 °C for 1 h and 30 min after which the solution was filtered through Celite and added dropwise to a solution of 6 N HCl (15 mL) at 90 °C. The solution was stirred for a further 2 h, and then the solvent was removed in vacuo. The product mixture was purified using C_{18} reversed-phase chromatography (MeOH/ H_2O /TFA) to give styelsamine D ditrifluoroacetate as a purple oil (0.068 g, 34%). ¹H, ¹³C, and HRMS data agreed with literature values.²⁰

Deoxyamphimedine (3) and Demethyldeoxyamphimedine (4). Paraformaldehyde (4.79 mg, 0.16 mmol) was added to a solution of styelsamine D ditrifluoroacetate (16.1 mg, 0.032 mmol) in acetic acid (2 mL) and stirred for 5 h at 60 °C and then left stirring overnight at rt. The acetic acid was then removed in vacuo, and the product mixture was purified using Sephadex LH-20 column chromatography (MeOH/TFA) to give, in order of elution, deoxyamphimedine (**3**, 13.1 mg, 48%) as a brown/yellow oil and demethyldeoxyamphimedine (**4**, 9.1 mg, 52%) as a brown oil. Repeating the reaction in the presence of increasing equivalents of paraformaldehyde gave **3** (58%) and **4** (34%) with 9.1 equiv of paraformaldehyde and **3** (66%), **4** (34%) with 15 equiv of paraformaldehyde.

Deoxyamphimedine (3). ¹H NMR (CD_3OD , 400 MHz) δ 9.88 (1H, s, H-9), 9.42 (1H, d, $J = 5.5$ Hz, H-12), 9.33–9.25 (2H, m, H-6, 11), 9.08 (1H, br s, H-5), 8.93 (1H, d, $J = 7.56$ Hz, H-4), 8.47 (1H, d, $J = 7.6$ Hz, H-1), 8.11 (1H, t, $J = 7.6$ Hz, H-2), 8.04 (1H, t, $J = 7.7$ Hz, H-3), 4.66 (3H, s, H_3 -14); ¹³C NMR (CD_3OD , 100 MHz) δ 179.2 (C-8), 151.4 (C-6), 149.4 (C-11), 149.4 (C-12a), 147.9 (C-9), 147.2 (C-7a), 146.6 (C-13a), 145.4 (C-12b), 139.8 (C-4b), 134.0 (C-2), 133.3

(C-1), 132.9 (C-3), 131.5 (C-8a), 125.2 (C-4), 124.5 (C-12), 124.2 (C-4a), 122.9 (C-5), 120.9 (C-12c), 49.0 (C-14); (+)-HRESIMS m/z 298.0966 [M] (calcd for $\text{C}_{19}\text{H}_{12}\text{N}_3\text{O}$, 298.0975).

Demethyldeoxyamphimedine (4). ¹H NMR (TFA-*d*/ CDCl_3 (2:1), 400 MHz) δ 9.87 (1H, s, H-9), 9.72 (1H, br s, H-12), 9.63 (1H, br s, H-5), 9.49 (1H, br s, H-6), 9.40 (1H, br s, H-11), 9.05 (1H, d, $J = 7.7$ Hz, H-4), 8.80 (1H, d, $J = 7.7$ Hz, H-1), 8.47 (1H, t, $J = 7.7$ Hz, H-3), 8.33 (1H, t, $J = 7.7$ Hz, H-2); ¹³C NMR (TFA-*d*/ CDCl_3 (2:1), 100 MHz) δ 173.7 (C-8), 150.6 (C-12a), 148.0 (C-13a), 146.5 (C-4b), 146.4 (C-11), 144.1 (C-9), 143.4 (C-12b), 141.5 (C-6), 138.2 (C-2), 138.1 (C-7a), 135.4 (C-3), 134.9 (C-1), 128.7 (C-8a), 126.8 (C-5), 126.2 (C-4), 125.0 (C-12), 121.3 (C-4a), signal due to C-12c was obscured by TFA-*d* peaks; ¹H NMR (CDCl_3 , 500 MHz) δ 9.72 (1H, s, H-9), 9.38 (1H, d, $J = 5.4$ Hz, H-6), 9.12 (1H, d, $J = 5.5$ Hz, H-12), 8.84 (1H, d, $J = 5.5$ Hz, H-11), 8.71 (1H, d, $J = 5.4$ Hz, H-5), 8.68 (1H, dd, $J = 8.4, 1.3$ Hz, H-4), 8.43 (1H, dd, $J = 8.4, 1.3$ Hz, H-1), 8.01 (1H, dt, $J = 8.4, 1.3$ Hz, H-2), 7.90 (1H, dt, $J = 8.4, 1.3$ Hz, H-3); ¹³C NMR (CDCl_3 , 125 MHz) δ 154.8, 150.7, 150.5, 147.3, 147.0, 145.7, 142.2, 138.3, 132.2, 132.0, 130.0, 126.6, 123.0, 122.4, 120.0, 119.2, 118.5 (one resonance not observed); (+)-HRESIMS m/z 306.0647 [$\text{M} + \text{Na}$]⁺ (calcd for $\text{C}_{18}\text{H}_9\text{N}_3\text{NaO}$, 306.0638).

Amphimedine (1). A solution of NaOH (1.02 mg, 0.025 mmol) in water (200 μL) and a solution of potassium ferricyanide (4.18 mg, 0.013 mmol) in water (200 μL) were added simultaneously to a stirred solution of deoxyamphimedine (**3**, 2.61 mg, 6.4 μmol) in water (500 μL) at 0 °C over a period of 10 min. After the dropwise addition, the reaction mixture was stirred for 25 min after which it was diluted with water (1 mL) and extracted with CH_2Cl_2 (5 × 3 mL). The combined organic extracts were dried (MgSO_4), and the solvent was removed in vacuo. The product mixture was purified using silica gel column chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 9:1) to give amphimedine (**1**) as a bright yellow powder (1.82 mg, 92%). Alternatively, deoxyamphimedine (1.41 mg, 3.4 μmol) was dissolved in DMSO (90 μL), and concd HCl (10 μL) was added. The solution was stirred at rt for 2 h. The solution was then neutralized by the addition of sat. aq NaHCO_3 and extracted with CH_2Cl_2 (5 × 3 mL), and the crude product was purified by LH-20 column chromatography (MeOH) to give amphimedine (**1**) (1.07 mg, 75%). R_f ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 9:1) 0.21; ¹H NMR (TFA-*d*/ CDCl_3 (2:1), 400 MHz) δ 9.39 (1H, s, H-9), 9.30 (1H, d, $J = 5.5$ Hz, H-12), 9.10 (2H, m, H-6, 11), 8.88 (1H, br s, H-5), 8.64 (1H, d, $J = 7.56$ Hz, H-4), 8.35 (1H, d, $J = 7.6$ Hz, H-1), 8.35 (1H, t, $J = 7.6$ Hz, H-2), 8.18 (1H, t, $J = 7.7$ Hz, H-3), 3.98 (3H, s, H_3 -14); ¹H NMR (CDCl_3 , 400 MHz) δ 9.30 (1H, d, $J = 5.5$ Hz, H-6), 8.80 (1H, s, H-9), 8.77–8.63 (2H, m, H-4, 5), 8.37 (1H, dd, $J = 8.1, 1.1$ Hz, H-1), 8.06 (1H, s, H-12), 7.99 (1H, dt, $J = 8.1, 1.1$ Hz, H-2), 7.87 (1H, dt, $J = 8.1, 1.1$ Hz, H-3), 3.80 (3H, s, H_3 -14); ¹³C NMR (TFA-*d*/ CDCl_3 (2:1), 100 MHz) δ 172.8 (C-8), 165.6 (C-11), 147.7 (C-13a), 147.3 (C-9), 145.8 (C-4b), 145.3 (C-12b), 143.5 (C-12a), 139.5 (C-6, C-7), 137.4 (C-2), 133.5 (C-1), 133.0 (C-3), 125.3 (C-4), 124.9 (C-5), 120.4 (C-4a), 118.7 (C-12c), 114.9 (C-12), 113.5 (C-12c), 40.0 (C-14); (+)-HRESIMS m/z 314.0931 [$\text{M} + \text{H}$]⁺ (calcd for $\text{C}_{19}\text{H}_{12}\text{N}_3\text{O}_2$, 314.0924).

General Procedure A: Alkylation of N-(3,4-Dimethoxyphenethyl)acetamide (12). The relevant alkyl halide (2–4 equiv) is added dropwise to a solution of *N*-(3,4-dimethoxyphenethyl)acetamide (**12**) (1 equiv) and sodium hydride (2 equiv) in THF/DMF (10:1, 5 mL). The reaction was allowed to stir at rt under N_2 atmosphere for 10 min after which the mixture was heated at reflux overnight. The solvent was then removed in vacuo, and the product mixture was dissolved in EtOAc and washed with sat. aq $\text{Na}_2\text{S}_2\text{O}_3$ and then dried (MgSO_4). The solvent was then removed in vacuo to yield the alkylated product.

General Procedure B: De-O-methylation of N-Alkyl-dimethoxyphenethylacetamides. To a stirred solution of the alkylated acetamide (**1** equiv) in CH_2Cl_2 was added a solution of BBr_3 (9 equiv) in CH_2Cl_2 dropwise at 0 °C under a N_2 atmosphere. The mixture was stirred for 5–6 h after which MeOH was added followed by washing with brine and water. The aqueous layer was extracted with EtOAc, and the organic extract was dried (MgSO_4) followed by removal of the solvent in vacuo to yield the demethylated product.

General Procedure C: Preparation of *N*-Alkyl Analogues of Styelsamine B. Kynuramine dihydrobromide (7, 1.05 equiv) was added to a stirred solution of the relevant *N*-dihydroxyphenylethyl-*N*-alkylacetamide (1 equiv) in MeOH-HOAc (2:1, 5 mL) under N₂ atmosphere followed by the addition of CeCl₃·7H₂O (0.15 equiv) and Ag₂O (2.2 equiv). The mixture was stirred at 40 °C for 2 h after which the solution was filtered through Celite and added dropwise to a solution of 6 N HCl (20 mL) at 90 °C. The solution was stirred for a further 30 min and then dried in vacuo. The product mixture was purified using C₂ reversed-phase flash (MeOH/H₂O/0.05% TFA) and Sephadex LH-20 column chromatography (MeOH/0.05% TFA) to yield styelsamine B analogues as the TFA salts.

General Procedure D: Preparation of *N*-Alkyl Analogues of Styelsamine D. A solution of *N*-alkyl styelsamine B and 6 N HCl was stirred for 30–50 h at 80 °C. Concentration of the reaction mixture under reduced pressure was followed by purification using C₁₈ reversed-phase flash column chromatography (MeOH/H₂O/0.05% TFA) to yield the styelsamine D analogues as di-TFA salts.

General Procedure E: Synthesis of *N*-alkyl Analogues of Demethyldeoxyamphimedine. Paraformaldehyde (5 equiv) was added to a solution of *N*-alkyl-styelsamine D (1 equiv) in acetic acid and stirred for 5–6 h at 60 °C and then left stirring overnight at rt. The acetic acid was then removed in vacuo, and the product mixture was purified using Sephadex LH-20 column chromatography (MeOH + 0.05% TFA) to yield *N*-alkyl analogues of demethyldeoxyamphimedine.

General Procedure F: Synthesis of *N*-Alkyl Analogues of Demethylamphimedine. A solution of NaOH (4 equiv) in water and a solution of potassium ferricyanide (2 equiv) in water were added dropwise simultaneously to a stirred solution of *N*-alkyl-demethyldeoxyamphimedine in water at 0 °C over a period of 10 min. After the addition, the reaction mixture was stirred for 20 min after which it was diluted with water and extracted with CH₂Cl₂. The combined organic layers were dried (MgSO₄), and the solvent was removed in vacuo. The product mixture was purified using silica gel column chromatography (CH₂Cl₂/MeOH, 9:1) to yield *N*-alkyl analogues of demethylamphimedine.

***N*-(3,4-Dimethoxyphenethyl)-*N*-methylacetamide (13).** Using general procedure A, *N*-(3,4-dimethoxyphenethyl)acetamide (12, 0.3 g, 1.34 mmol), methyl iodide (0.67 g, 0.29 mL, 4.7 mmol), and sodium hydride (64.5 mg, 2.69 mmol) afforded 13 as a yellow oil (0.31 g, 97%) in a 1:1 mixture of rotamers. *R_f* (100% CH₂Cl₂) 0.17; IR (ATR) ν_{\max} 2933, 1514, 1626, 1261, 1236 cm⁻¹. Rotamer 1: ¹H NMR (CDCl₃, 400 MHz) δ 6.81 (1H, d, *J* = 8.2 Hz, H-8), 6.76 (1H, obscured, H-5), 6.69 (1H, dd, *J* = 1.9, 8.2 Hz, H-9), 3.86 (3H, s, H₃-13), 3.85 (3H, s, H₃-14), 3.49 (2H, t, *J* = 7.0 Hz, H₂-2), 2.93 (3H, s, H₃-10), 2.81–2.78 (2H, m, H₂-3), 1.84 (3H, s, H₃-12); ¹³C NMR (CDCl₃, 100 MHz) δ 170.5 (C-11), 148.9 (C-6), 147.7 (C-7), 130.6 (C-4), 120.5 (C-9), 111.9 (C-5), 111.4 (C-8), 55.7 (C-13, 14), 52.4 (C-2), 34.0 (C-3), 33.1 (C-10), 20.7 (C-12). Rotamer 2: ¹H NMR (CDCl₃, 400 MHz) δ 6.80 (1H, d, *J* = 7.9 Hz, H-8), 6.75 (1H, dd, *J* = 7.9, 2.0 Hz, H-9), 6.66 (1H, d, *J* = 2.0 Hz, H-9), 3.86 (3H, s, H₃-13), 3.84 (3H, s, H₃-14), 3.56 (2H, t, *J* = 7.8 Hz, H₂-2), 2.89 (2H, s, H₃-10), 2.78–2.76 (2H, m, H₂-3), 2.06 (3H, s, H₃-12); ¹³C NMR (CDCl₃, 100 MHz) δ 170.3 (C-11), 148.7 (C-6), 147.3 (C-7), 131.5 (C-4), 120.6 (C-9), 111.8 (C-5), 111.2 (C-8), 55.7 (C-13, 14), 49.5 (C-2), 36.6 (C-10), 33.1 (C-3), 21.7 (C-12); (+)-HRESIMS *m/z* 260.1262 [M + Na]⁺ (calcd for C₁₃H₁₉NNaO₃, 260.1257). ¹H and ¹³C signals could not be assigned to specific rotamers.

***N*-(3,4-Dihydroxyphenethyl)-*N*-methylacetamide (16).** Using general procedure B, *N*-(3,4-dimethoxyphenethyl)-*N*-methylacetamide (13, 50.0 mg, 0.21 mmol) and BBr₃ (0.48 g, 1.90 mmol, 0.18 mL) afforded 16 as a yellow oil (27.0 mg, 61%) in a 1:1 mixture of rotamers. IR (ATR) ν_{\max} 3187, 1583, 1440, 1408, 1233, 1113 cm⁻¹. Rotamer 1: ¹H NMR (CDCl₃, 400 MHz) δ 6.70 (1H, d, *J* = 8.1 Hz, H-8), 6.65–6.64 (1H, m, H-5), 6.54–6.52 (1H, m, H-9), 3.50–3.46 (2H, m, H₂-2), 2.91 (3H, s, H₃-10), 2.66 (2H, t, *J* = 7.1 Hz, H₂-3), 2.04 (3H, s, H₃-12); ¹³C NMR (CDCl₃, 100 MHz) δ 173.2 (C-11), 146.4 (C-6), 145.1 (C-7), 131.9 (C-4), 121.2 (C-9), 117.1 (C-5), 116.5 (C-8), 51.1 (C-2), 37.3 (C-10), 33.84 (C-3), 21.7 (C-12). Rotamer 2: ¹H NMR

(CDCl₃, 400 MHz) δ 6.68 (1H, d, *J* = 8.0 Hz, H-8), 6.64–6.63 (1H, m, H-5), 6.52–6.50 (1H, m, H-9), 3.53–3.50 (2H, m, H₂-2), 2.89 (3H, s, H₃-10), 2.71 (2H, t, *J* = 6.7 Hz, H₂-3), 1.76 (3H, s, H₃-12); ¹³C NMR (CDCl₃, 100 MHz) δ 173.5 (C-11), 146.2 (C-6), 144.8 (C-7), 131.3 (C-4), 121.1 (C-9), 116.9 (C-5), 116.4 (C-8), 53.8 (C-2), 34.6 (C-3), 33.79 (C-10), 20.8 (C-12); (+)-HRESIMS *m/z* 232.0948 [M + Na]⁺ (calcd for C₁₁H₁₅NNaO₃, 232.0944). ¹H and ¹³C signals could not be assigned to specific rotamers.

***N*-(3,4-Dimethoxyphenethyl)-*N*-ethylacetamide (14).** Using general procedure A, *N*-(3,4-dimethoxyphenethyl)acetamide (12, 0.46 g, 1.80 mmol), ethyl bromide (0.39 g, 0.27 mL, 3.6 mmol), and sodium hydride (0.14 g, 3.6 mmol) afforded 14 as a pale yellow oil (0.52 g, quantitative yield) in a mixture of rotamers. *R_f* (30% EtOAc/Hex) 0.12; IR (ATR) ν_{\max} 2935, 1623, 1515, 1420, 1261, 1236 cm⁻¹. Rotamer 1: ¹H NMR (CDCl₃, 500 MHz) δ 6.82 (1H, d, *J* = 7.8 Hz, H-8), 6.70 (1H, dd, *J* = 7.8, 2.0 Hz, H-9), 6.66 (1H, d, *J* = 2.0 Hz, H-5), 3.88 (3H, s, H₃-14), 3.86 (3H, s, H₃-15), 3.45 (2H, t, *J* = 7.3 Hz, H₂-2), 3.40 (2H, q, *J* = 7.3 Hz, H₂-10), 2.79–2.76 (2H, m, H₂-3), 1.91 (3H, s, H₃-13), 1.16–1.11 (3H, m, H₃-11); ¹³C NMR (CDCl₃, 125 MHz) δ 170.2 (C-12), 149.2 (C-6), 148.0 (C-7), 130.9 (C-4), 120.9 (C-9), 112.2 (C-5), 111.4 (C-8), 56.0 (C-13, 14), 50.2 (C-2), 40.5 (C-10), 35.1 (C-3), 21.6 (C-13), 13.0 (C-11). Rotamer 2: ¹H NMR (CDCl₃, 500 MHz) δ 6.80–6.78 (1H, m, H-5), 6.77–6.74 (2H, m, H-8, 9), 3.88 (3H, s, H₃-14), 3.86 (3H, s, H₃-15), 3.50 (2H, t, *J* = 7.4 Hz, H₂-2), 3.20 (2H, q, *J* = 7.1 Hz, H₂-10), 2.82–2.79 (2H, m, H₂-3), 2.10 (3H, s, H₃-13), 1.16–1.11 (3H, m, H₃-11); ¹³C NMR (CDCl₃, 125 MHz) δ 170.1 (C-12), 149.0 (C-6), 147.6 (C-7), 132.1 (C-4), 120.8 (C-9), 112.1 (C-5), 111.6 (C-8), 56.0 (C-13, 14), 47.8 (C-2), 44.1 (C-10), 33.9 (C-3), 21.5 (C-13), 14.1 (C-11); (+)-HRESIMS *m/z* 274.1414 [M + Na]⁺ (calcd for C₁₄H₂₁NNaO₃, 274.1414). ¹H and ¹³C signals could not be assigned to specific rotamers.

***N*-(3,4-Dihydroxyphenethyl)-*N*-ethylacetamide (17).** Using general procedure B, *N*-(3,4-dimethoxyphenethyl)-*N*-ethylacetamide (14, 0.38 g, 1.5 mmol) and BBr₃ (3.0 g, 12.1 mmol, 1.10 mL) afforded 17 as a pale brown gum (0.33 g, 98% yield) in a mixture of rotamers. IR (ATR) ν_{\max} 3179, 2977, 1588, 1441, 1280 cm⁻¹. Rotamer 1: ¹H NMR (CD₃OD, 500 MHz) δ 6.71–6.67 (1H, m, H-8), 6.66–6.62 (1H, m, H-5), 6.54–6.49 (1H, m, H-9), 3.48 (2H, t, *J* = 7.1, H₂-2), 3.36 (2H, q, *J* = 7.2 Hz, H₂-10), 2.72 (2H, obscured, H₂-3), 2.08 (3H, s, H₃-13), 1.11–1.08 (3H, m, H₃-11); ¹³C NMR (CDCl₃, 125 MHz) δ 173.1 (C-12), 146.5 (C-6), 145.1 (C-7), 131.3 (C-4), 121.3 (C-9), 117.1 (C-5), 116.5 (C-8), 51.4 (C-2), 41.7 (C-10), 35.2 (C-3), 21.2 (C-13), 12.9 (C-11). Rotamer 2: ¹H NMR (CD₃OD, 500 MHz) δ 6.71–6.67 (1H, m, H-8), 6.66–6.62 (1H, m, H-5), 6.54–6.49 (1H, m, H-9), 3.44 (2H, t, *J* = 6.8, H₂-2), 3.25 (2H, q, *J* = 7.2 Hz, H₂-10), 2.67 (2H, obscured, H₂-3), 1.81 (3H, s, H₃-13), 1.14–1.11 (3H, m, H₃-11); ¹³C NMR (CDCl₃, 125 MHz) δ 172.8 (C-12), 146.3 (C-6), 144.8 (C-7), 132.1 (C-4), 121.1 (C-9), 116.9 (C-5), 116.4 (C-8), 49.1 (C-2), 45.2 (C-10), 34.3 (C-3), 21.2 (C-13), 14.0 (C-11); (+)-HRESIMS *m/z* 224.1283 [M + H]⁺ (calcd for C₁₂H₁₈NO₃, 224.1281). ¹H and ¹³C signals could not be assigned to specific rotamers.

***N*-(3,4-Dimethoxyphenethyl)-*N*-benzylacetamide (15).** Using general procedure A, *N*-(3,4-dimethoxyphenethyl)acetamide (12, 0.54 g, 2.42 mmol), benzyl bromide (0.83 g, 0.58 mL, 4.8 mmol), and sodium hydride (0.19 g, 4.8 mmol) afforded 15 as a pale yellow oil (0.73 g, 96%) in a mixture of rotamers. *R_f* (50% EtOAc/Hex) 0.16; IR (ATR) ν_{\max} 2934, 1634, 1515, 1419, 1261, 1027 cm⁻¹. Rotamer 1: ¹H NMR (CDCl₃, 500 MHz) δ 7.37–7.34 (2H, m, H-17, 19), 7.31–7.27 (2H, m, H-16, 20), 7.26–7.23 (1H, m, H-18), 6.81–6.76 (1H, m, H-8), 6.65 (1H, dd, *J* = 8.5, 1.9 Hz, H-9), 6.58 (1H, d, *J* = 1.9 Hz, H-5), 4.60 (2H, s, H₂-14), 3.85 (6H, s, H₃-12, 13), 3.42 (2H, t, *J* = 7.2 Hz, H₂-2), 2.74 (2H, t, *J* = 7.2 Hz, H₂-3), 2.02 (3H, s, CH₃-11); ¹³C NMR (CDCl₃, 125 MHz) δ 170.8 (C-10), 149.0 (C-6), 148.0 (C-7), 137.8 (C-15), 130.9 (C-4), 129.0 (C-17, 18), 128.3 (C-16, 20), 127.7 (C-18), 120.8 (C-9), 112.1 (C-5), 111.6 (C-8), 56.0 (C-12, 13), 49.7 (C-2), 48.3 (C-14), 33.7 (C-3), 21.4 (C-11). Rotamer 2: ¹H NMR (CDCl₃, 500 MHz) δ 7.37–7.34 (2H, m, H-17, 19), 7.26–7.23 (1H, m, H-18), 7.13 (2H, d, *J* = 7.6 Hz, H-16, 20), 6.81–6.76 (1H, m, H-8), 6.72–6.69 (2H, m, H-5, 9), 6.58 (1H, d, *J* = 1.9 Hz, H-5), 4.36 (2H, s, H₂-14), 3.85 (6H, s, OCH₃-12, 13), 3.56 (2H, t, *J* = 7.3 Hz, H₂-2),

2.80 (2H, t, $J = 7.3$ Hz, H₂-3), 2.12 (3H, s, CH₃-11); ¹³C NMR (CDCl₃, 125 MHz) δ 171.0 (C-10), 149.2 (C-6), 147.6 (C-7), 136.9 (C-15), 131.9 (C-4), 129.0 (C-17, 18), 127.5 (C-18), 126.4 (C-16, 20), 120.8 (C-9), 112.0 (C-5), 111.4 (C-8), 56.0 (C-12, 13), 52.9 (C-14), 48.4 (C-2), 34.6 (C-3), 22.0 (C-11); (+)-HRESIMS m/z 336.1563 [M + Na]⁺ (calcd for C₁₉H₂₃NNaO₃, 336.1570). ¹H and ¹³C signals could not be assigned to specific rotamers.

***N*-(3,4-Dihydroxyphenethyl)-*N*-benzylacetamide (18).** Using general procedure B, *N*-(3,4-dimethoxyphenethyl)-*N*-benzylacetamide (15, 0.41 g, 1.31 mmol) and BBr₃ (2.62 g, 10.0 mmol, 0.97 mL) afforded 18 as a white gum (0.36 g, 97%) in a mixture of rotamers. IR (ATR) ν_{\max} 3207, 1596, 1440, 1419, 1363, 1194 cm⁻¹. Rotamer 1: ¹H NMR (CDCl₃, 500 MHz) δ 7.41–7.34 (2H, m, H-15, 17), 7.29–7.25 (1H, m, H-16), 7.16 (2H, d, $J = 8.0$ Hz H-14, 18), 6.72–6.66 (1H, m, H-8), 6.62–6.59 (1H, m, H-5), 6.51–6.45 (1H, m, H-9), 4.43 (2H, s, H₂-12), 3.46 (2H, t, $J = 7.5$ Hz, H₂-2), 2.66 (2H, t, $J = 7.5$ Hz, H₂-3), 1.94 (3H, s, CH₃-11); ¹³C NMR (CDCl₃, 125 MHz) δ 173.6 (C-10), 146.5 (C-6), 145.1 (C-7), 138.2 (C-13), 132.0 (C-4), 129.9 (C-15, 17), 128.6 (C-16), 127.7 (C-14, 18), 121.3 (C-9), 117.0 (C-5), 116.5 (C-8), 53.8 (C-12), 49.8 (C-2), 34.1 (C-3), 21.2 (C-11). Rotamer 2: ¹H NMR (CDCl₃, 500 MHz) δ 7.34–7.30 (2H, m, H-15, 17), 7.29–7.25 (1H, m, H-16), 7.23–7.22 (2H, m, H-14, 18), 6.72–6.66 (1H, m, H-8), 6.62–6.59 (1H, m, H-5), 6.51–6.45 (1H, m, H-9), 4.57 (2H, s, H₂-12), 3.43 (2H, t, $J = 7.2$ Hz, H₂-2), 2.68 (2H, t, $J = 7.2$ Hz, H₂-3), 2.11 (3H, s, CH₃-11); ¹³C NMR (CDCl₃, 125 MHz) δ 173.6 (C-10), 146.3 (C-6), 144.8 (C-7), 138.8 (C-13), 131.3 (C-4), 129.6 (C-15, 17), 129.0 (C-14, 18), 128.4 (C-16), 121.1 (C-9), 116.9 (C-5), 116.4 (C-8), 51.0 (C-2), 49.0 (C-12), 34.8 (C-3), 21.8 (C-11); (+)-HRESIMS m/z 308.1253 [M + Na]⁺ (calcd for C₁₇H₁₉NNaO₃, 308.1257). ¹H and ¹³C signals could not be assigned to specific rotamers.

***N*-Methyl-styelsamine B (19).** Using general procedure C, kynuramine dihydrobromide (7, 0.11 g, 0.35 mmol), *N*-(3,4-dihydroxyphenethyl)-*N*-methylacetamide (16, 0.075 g, 0.33 mmol), CeCl₃·7H₂O (0.019 g, 0.005 mmol), and Ag₂O (0.17 g, 0.73 mmol) afforded 19 as a purple oil (TFA salt, 15.1 mg, 10% yield). $R_t = 8.27$ min; IR (ATR) ν_{\max} 3098, 1677, 1619, 1582, 1197, 1132 cm⁻¹; ¹H NMR (CD₃OD, 500 MHz) δ 7.99–7.94 (1H, m, H-2), 7.90–7.85 (1H, m, H-4), 7.60–7.54 (1H, m, H-6), 7.53–7.47 (1H, m, H-7), 7.27–7.24 (1H, s, H-10), 7.23–7.11 (1H, m, H-3), 7.17–7.11 (1H, m, H-5), 3.40–3.34 (2H, m, H₂-14), 3.19 (3H, s, H₃-17), 2.91–2.82 (2H, m, H₂-13), 2.20 (3H, m, H₃-16); ¹³C NMR (CD₃OD, 125 MHz) δ 174.5 (C-15), 151.3 (C-3a), 143.5 (C-2), 142.6 (C-7a), 138.1 (C-11), 136.3 (C-6), 130.3 (C-8a), 127.6 (C-11a), 126.2 (C-4), 124.0 (C-5), 122.7 (C-10), 121.9 (C-11b), 119.1 (C-7), 116.9 (C-9), 11.5 (C-3b), 105.7 (C-3), 48.4 (C-13), 37.9 (C-16), 30.3 (C-12), 21.6 (C-15); ¹H NMR (DMSO-*d*₆, 400 MHz) δ 13.47 (1H, br s, NH-1), 11.54 (1H, br s, NH-8), 10.83 (1H, br s, OH-12), 8.24 (1H, d, $J = 6.6$ Hz, H-2), 8.20 (1H, d, $J = 8.6$ Hz, H-4), 7.70 (1H, t, $J = 8.6$ Hz, H-6), 7.63 (1H, d, $J = 8.6$ Hz, H-7), 7.54 (1H, d, $J = 6.6$ Hz, H-3), 7.42 (1H, s, H-10), 7.23 (1H, t, $J = 8.6$ Hz, H-5), 3.47–3.41 (2H, m, H₂-14), 3.10 (3H, s, H₃-17), 3.05–2.98 (2H, m, H₂-13), 2.10 (3H, s, H₃-16); ¹³C NMR (DMSO-*d*₆, 100 MHz) δ 171.7 (C-15), 149.3 (C-3a), 143.4 (C-2), 141.0 (C-7a), 136.6 (C-11), 135.1 (C-6), 128.5 (C-8a), 125.9 (C-11a), 125.6 (C-4), 122.5 (C-5), 121.4 (C-10), 120.3 (C-11b), 117.7 (C-7), 115.7 (C-9), 113.9 (C-3b), 105.0 (C-3), 46.5 (C-14), 37.0 (C-17), 28.6 (C-13), 21.5 (C-16); (+)-HRESIMS m/z 334.1562 [M + H]⁺ (calcd for C₂₀H₂₀N₃O₂, 334.1550).

***N*-Ethyl-styelsamine B (20).** Using general procedure C, kynuramine dihydrobromide (7, 0.16 g, 0.50 mmol), *N*-(3,4-dihydroxyphenethyl)-*N*-ethylacetamide (17, 0.11 g, 0.48 mmol), CeCl₃·7H₂O (0.027 g, 0.072 mmol), and Ag₂O (0.24 g, 1.10 mmol) afforded 20 as a purple oil (TFA salt, 27.2 mg, 12% yield).

$R_t = 8.98$ min; IR (ATR) ν_{\max} 3140, 2980, 1586, 1506, 1426, 1194 cm⁻¹; ¹H NMR (CD₃OD, 500 MHz) δ 7.92 (1H, d, $J = 6.7$ Hz, H-2), 7.82 (1H, d, $J = 8.3$ Hz, H-4), 7.54 (1H, dt, $J = 7.4, 1.2$ Hz, H-6), 7.45 (1H, d, $J = 7.4$ Hz, H-7), 7.21 (1H, s, H-10), 7.15–7.11 (2H, m, H-3, 5), 3.52 (2H, q, $J = 7.1$ Hz, H₂-16), 3.29 (2H, obscured, H₂-13), 2.79 (2H, t, $J = 7.0$ Hz, H₂-12), 2.23 (3H, s, H₃-15), 1.28 (3H, t, $J = 7.1$ Hz, H₃-17); ¹³C NMR (CD₃OD, 125 MHz) δ 173.9 (C-14), 150.8 (C-3a),

143.3 (C-2), 142.3 (C-7a), 137.9 (C-11), 136.1 (C-6), 129.9 (C-8a), 127.2 (C-11a), 126.0 (C-4), 123.8 (C-5), 122.6 (C-10), 121.5 (C-11b), 119.0 (C-7), 116.8 (C-9), 115.2 (C-3b), 105.5 (C-3), 46.4 (C-16), 46.3 (C-13), 31.5 (C-12), 21.2 (C-15), 14.7 (C-17); (+)-HRESIMS m/z 348.1716 [M + H]⁺ (calcd for C₂₁H₂₂N₃O₂, 348.1707).

***N*-Benzyl-styelsamine B (21).** Using general procedure C, kynuramine dihydrobromide (7, 0.12 g, 0.37 mmol), *N*-(3,4-dihydroxyphenethyl)-*N*-benzylacetamide (18, 0.10 g, 0.35 mmol), CeCl₃·7H₂O (0.020 g, 0.05 mmol), and Ag₂O (0.18 g, 0.77 mmol) afforded 21 as a purple oil (TFA salt, 20.5 mg, 11% yield). $R_t = 9.53$ min; IR (ATR) ν_{\max} 3423, 2949, 1661, 1582, 1250, 1130 cm⁻¹; ¹H NMR (CD₃OD, 500 MHz) δ 7.93 (1H, br s, H-2), 7.89–7.83 (1H, m, H-4), 7.58–7.52 (1H, m, H-6), 7.53–7.47 (1H, m, H-7), 7.42 (2H, t, $J = 7.7$ Hz, H-19, 21), 7.35 (1H, d, $J = 7.7$ Hz, H-20), 7.30 (2H, d, $J = 7.7$ Hz, H-18, 22), 7.19–7.12 (2H, m, H-3, 5), 7.04 (1H, s, H-10), 4.72 (2H, s, H₂-16), 3.36–3.31 (2H, m, H₂-13), 2.74–2.64 (2H, m, H₂-12), 2.30 (3H, s, H₃-15); ¹³C NMR (CD₃OD, 125 MHz) δ 174.7 (C-14), 150.9 (C-3a), 143.3 (C-2), 142.3 (C-7a), 138.0 (C-11), 137.9 (C-17), 136.2 (C-6), 130.1 (C-19, 21), 129.9 (C-8a), 129.0 (C-20), 128.2 (C-18, 22), 127.3 (C-11a), 126.0 (C-4), 123.9 (C-5), 122.5 (C-10), 121.5 (C-11b), 119.0 (C-7), 116.7 (C-9), 115.3 (C-3b), 105.5 (C-3), 54.8 (C-16), 47.0 (C-13), 31.0 (C-12), 21.8 (C-15); (+)-HRESIMS m/z 410.1859 [M + H]⁺ (calcd for C₂₆H₂₄N₃O₂, 410.1863).

***N*-Methyl-styelsamine D (22).** Using general procedure D, *N*-methyl-styelsamine B (19, 15.1 mg, 0.03 mmol) and 6 N HCl (8 mL) afforded 22 as a purple oil (bis-TFA salt, 7.07 mg, 41% [71% yield based on recovered starting material]). $R_t = 7.01$ min; IR (ATR) ν_{\max} 3098, 1677, 1619, 1582, 1197, 1132 cm⁻¹; ¹H NMR (CD₃OD, 500 MHz) δ 8.19 (1H, d, $J = 6.6$ Hz, H-2), 8.12 (1H, d, $J = 8.2$ Hz, H-4), 7.90 (1H, d, $J = 8.2$ Hz, H-7), 7.67 (1H, t, $J = 8.2$ Hz, H-6), 7.53 (1H, d, $J = 6.3$ Hz, H-3), 7.49 (1H, s, H-10), 7.26 (1H, t, $J = 8.2$ Hz, H-5), 3.41–3.36 (2H, m, H₂-12), 3.27–3.31 (2H, m, H₂-13), 2.78 (3H, s, H₃-15); ¹³C NMR (CD₃OD, 125 MHz) δ 151.5 (C-3a), 143.9 (C-2), 142.7 (C-7a), 138.6 (C-11), 136.4 (C-6), 130.3 (C-8a), 128.7 (C-11a), 126.3 (C-4), 124.2 (C-5), 122.8 (C-10), 122.2 (C-11b), 119.2 (C-7), 115.7 (C-3b), 114.4 (C-9), 106.5 (C-3), 49.0 (C-13), 33.8 (C-15), 28.7 (C-12); ¹H NMR (DMSO-*d*₆, 500 MHz) δ 10.98 (2H, br s, NH-8), 8.70 (2H, br s, NH-14), 8.32 (1H, d, $J = 6.3$ Hz, H-2), 8.25 (1H, d, $J = 8.2$ Hz, H-4), 7.81 (1H, d, $J = 8.7$ Hz, H-7), 7.71 (1H, t, $J = 8.7$ Hz, H-6), 7.62 (1H, d, $J = 6.3$ Hz, H-3), 7.49 (1H, s, H-10), 7.25 (1H, t, $J = 8.2$ Hz, H-5), 3.28 (2H, t, $J = 6.9$ Hz, H₂-12), 3.22–3.18 (2H, m, H₂-13), 2.62 (3H, t, $J = 4.7$ Hz, H₃-15); ¹³C NMR (DMSO-*d*₆, 125 MHz) δ 150.0 (C-3a), 143.6 (C-2), 141.1 (C-7a), 137.1 (C-11), 135.0 (C-6), 128.5 (C-8a), 126.8 (C-11a), 125.5 (–4), 122.7 (C-5), 121.9 (C-10), 120.6 (C-11b), 117.9 (C-7), 113.6 (C-9), 115.5 (C-3b), 105.4 (C-3), 47.0 (C-13), 32.7 (C-15), 27.1 (C-12); (+)-HRESIMS m/z 292.1448 [M + H]⁺ (calcd for C₁₈H₁₈N₃O, 292.1444).

***N*-Ethyl-styelsamine D (23).** Using general procedure D, *N*-ethyl-styelsamine B (20, 11.9 mg, 0.03 mmol) and 6 N HCl (8 mL) afforded 23 as a purple oil (bis-TFA salt, 3.95 mg, 29% [51% based on recovered starting material]). $R_t = 7.47$ min; IR (ATR) ν_{\max} 3403, 2949, 1672, 1583, 1250, 1132 cm⁻¹; ¹H NMR (CD₃OD, 500 MHz) δ 8.10 (1H, br s, H-2), 8.02 (1H, d, $J = 7.8$ Hz, H-4), 7.68 (1H, d, $J = 7.8$ Hz, H-7), 7.63 (1H, t, $J = 7.8$ Hz, H-6), 7.42–4.38 (2H, m, H-3, 10), 7.22 (1H, t, $J = 7.8$ Hz, H-5), 3.28–3.24 (4H, m, H₂-12, 13), 3.12 (2H, q, $J = 7.3$ Hz, H₂-15), 1.34 (3H, t, $J = 7.3$ Hz, H₃-16); ¹³C NMR (CD₃OD, 125 MHz) δ 151.3 (C-3a), 143.7 (C-2), 142.5 (C-7a), 138.6 (C-11), 136.4 (C-6), 130.0 (C-8a), 128.4 (C-11a), 126.1 (C-4), 124.2 (C-5), 122.8 (C-10), 122.0 (C-11b), 119.1 (C-7), 115.5 (C-3b), 114.5 (C-9), 106.2 (C-3), 47.1 (C-13), 44.3 (C-13), 28.7 (C-12), 11.4 (C-16); (+)-HRESIMS m/z 306.1597 [M + H]⁺ (calcd for C₁₉H₂₀N₃O, 306.1601).

***N*-Benzyl-styelsamine D (24).** Using general procedure D, *N*-benzyl-styelsamine B (21, 20.4 mg, 0.04 mmol) and 6 N HCl (8 mL) afforded 24 as a purple oil (bis-TFA salt, 9.44 mg, 41% [71% based upon recovered starting material]). $R_t = 8.52$ min; IR (ATR) ν_{\max} 3402, 2949, 1679, 1584, 1250, 1141, 1030 cm⁻¹; ¹H NMR (CD₃OD, 500 MHz) δ 8.12 (1H, d, $J = 6.5$ Hz, H-2), 8.00 (1H, d, $J = 8.2$ Hz, H-4), 7.87 (1H, d, $J = 8.0$ Hz, H-7), 7.61 (1H, t, $J = 8.0$ Hz, H-6), 7.59–

7.57 (2H, m, H-16, 20), 7.46–7.43 (3H, m, H-17, 18, 19), 7.41 (1H, d, $J = 6.5$ Hz, H-3), 7.39 (1H, s, H-10), 7.20 (1H, t, $J = 8.2$ Hz, H-5), 4.28 (2H, s, H₂-14), 3.36–3.34 (2H, m, H₂-12), 3.34–3.32 (2H, m, H₂-13); ¹³C NMR (CD₃OD, 125 MHz) δ 151.2 (C-3a), 143.7 (C-2), 142.5 (C-7a), 138.5 (C-11), 136.3 (C-6), 132.5 (C-15), 131.1 (C-16, 20), 130.7 (C-18), 130.3 (C-17, 19), 129.9 (C-8a), 128.3 (C-11a), 126.1 (C-4), 124.2 (C-5), 122.7 (C-10), 121.9 (C-11b), 119.1 (C-7), 115.5 (C-3b), 114.5 (C-9), 106.3 (C-3), 52.5 (C-14), 47.2 (C-13), 28.8 (C-12); (+)-HRESIMS m/z 368.1754 [M + H]⁺ (calcd for C₂₄H₂₂N₃O, 368.1757).

N-Ethyl-demethyldeoxyamphimedine (25). Using general procedure E, N-ethyl-styelsamine D (23, 11.5 mg, 0.02 mmol), paraformaldehyde (4.1 mg, 0.14 mmol), and acetic acid (2 mL) afforded 25 as a dark yellow powder (TFA salt, 7.61 mg, 83% yield). $R_f = 8.28$ min; IR (ATR) ν_{\max} 3401, 1671, 1427, 1183, 1110, 1032 cm⁻¹; ¹H NMR (CD₃OD, 500 MHz) δ 9.95 (1H, s, H-9), 9.46 (1H, d, $J = 5.5$ Hz, H-12), 9.39 (1H, d, $J = 5.5$ Hz, H-11), 9.31 (1H, d, $J = 4.9$ Hz, H-6), 9.10 (1H, d, $J = 4.9$ Hz, H-5), 8.94 (1H, d, $J = 8.0$ Hz, H-4), 8.49 (1H, d, $J = 8.0$ Hz, H-1), 8.12 (1H, t, $J = 8.0$ Hz, H-2), 8.04 (1H, t, $J = 8.0$ Hz, H-3), 4.94 (2H, q, $J = 7.2$ Hz, H₂-14), 1.82 (3H, t, $J = 7.2$ Hz, H₃-15); ¹³C NMR (CD₃OD, 125 MHz) δ 179.2 (C-8), 151.4 (C-6), 149.7 (C-12a), 148.2 (C-11), 147.2 (C-7a), 146.8 (C-9), 146.7 (C-13a), 145.5 (C-12b), 139.8 (C-4b), 134.0 (C-2), 133.3 (C-1), 133.0 (C-3), 132.0 (C-8a), 125.2 (C-4), 125.0 (C-12), 124.2 (C-4a), 122.9 (C-5), 120.9 (C-12c), 59.1 (C-14), 16.8 (C-15); (+)-HRESIMS m/z 312.1125 [M]⁺ (calcd for C₂₀H₁₄N₃O, 312.1131).

N-Benzyl-demethyldeoxyamphimedine (26). Using general procedure E, N-benzyl-styelsamine D (24, 8.1 mg, 0.02 mmol), paraformaldehyde (2.5 mg, 0.08 mmol), and acetic acid (1.5 mL) afforded 26 as a dark yellow powder (TFA salt, 6.04 mg, 74%). $R_f = 9.07$ min; IR (ATR) ν_{\max} 3408, 1691, 1636, 1250, 1129 cm⁻¹; ¹H NMR (CD₃OD, 500 MHz) δ 10.02 (1H, s, H-9), 9.49 (1H, d, $J = 6.5$ Hz, H-12), 9.38 (1H, d, $J = 6.5$ Hz, H-11), 9.36 (1H, d, $J = 5.3$ Hz, H-6), 9.16 (1H, d, $J = 5.3$ Hz, H-5), 9.00 (1H, d, $J = 8.0$ Hz, H-4), 8.53 (1H, d, $J = 8.0$ Hz, H-1), 8.14 (1H, t, $J = 8.0$ Hz, H-2), 8.08 (1H, t, $J = 8.0$ Hz, H-3), 7.69–7.63 (2H, m, H-16, 20), 7.56–7.51 (3H, 17, 18, 19), 6.09 (2H, s, H₂-14); ¹³C NMR (CD₃OD, 125 MHz) δ 179.2 (C-8), 151.4 (C-6), 150.2 (C-12a), 148.2 (C-11), 147.3 (C-7a)^a, 146.8 (C-9, 13a), 145.6 (C-12b)^a, 139.9 (C-4b), 134.3 (C-15), 134.0 (C-2), 133.3 (C-1), 133.0 (C-3), 132.4 (C-8a), 131.3 (C-18), 130.9 (C-17, 19), 130.5 (C-16, 20), 125.3 (C-4, 12), 124.4 (C-4a), 122.9 (C-5), 121.1 (C-12c), 66.1 (C-14); (+)-HRESIMS m/z 374.1275 [M] (calcd for C₂₅H₁₆N₃O, 374.1288).

N-Ethyl-demethylamphimedine (27). Using general procedure F, N-ethyl-demethyldeoxyamphimedine (25, 4.61 mg, 0.011 mmol), NaOH (1.73 mg, 0.043 mmol, in 0.3 mL of water), and potassium ferricyanide (7.14 mg, 0.022 mmol, in 0.3 mL of water) afforded 27 as a yellow powder (3.01 mg, 85%). R_f (CH₂Cl₂/MeOH, 9:1) 0.18; IR (ATR) ν_{\max} 3408, 2924, 1738, 1638, 1217, 1090 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 9.29 (1H, br s, H-6), 8.79 (1H, s, H-9), 8.67–8.57 (2H, m, H-4, 5), 8.35 (1H, d, $J = 7.8$ Hz, H-1), 8.01 (1H, s, H-12), 7.98 (1H, t, $J = 7.8$ Hz, H-2), 7.86 (1H, t, $J = 7.8$ Hz, H-3), 4.24 (2H, q, $J = 7.4$ Hz, H₂-14), 1.54 (3H, t, $J = 7.4$ Hz, H₃-15); ¹³C NMR (CDCl₃, 125 MHz) δ 179.1 (C-8), 162.5 (C-11), 150.0 (C-6), 147.7 (C-7a), 146.7 (C-12b), 145.4 (C-13a), 144.0 (C-9), 142.9 (C-12a), 138.4 (C-4b), 132.1 (C-2), 131.9 (C-1), 129.6 (C-3), 123.0 (C-4), 122.3 (C-4a), 119.9 (C-12c), 119.4 (C-5), 114.6 (C-12), 113.8 (C-8a), 46.2 (C-14), 14.9 (C-15); (+)-HRESIMS m/z 350.0890 [M + Na]⁺ (calcd for C₂₀H₁₃N₃NaO₂, 350.0900).

N-Benzyl-demethylamphimedine (28). Using general procedure F, N-benzyl-demethyldeoxyamphimedine (26, 7.65 mg, 0.016 mmol), NaOH (2.51 mg, 0.063 mmol, in 0.4 mL of water), and potassium ferricyanide (10.3 mg, 0.031 mmol, in 0.4 mL of water) afforded 28 as a poorly soluble yellow powder (2.10 mg, 34%). Benzyl derivative 28 is poorly soluble in most solvents and thus characterization was limited to ¹H NMR and HRESIMS. R_f (CH₂Cl₂/MeOH, 9:1) 0.26; ¹H NMR (CDCl₃, 500 MHz) δ 9.30 (1H, d, $J = 5.6$ Hz, H-6), 8.82 (1H, s, H-9), 8.67–8.63 (2H, m, H-4, 5), 8.39 (1H, d, $J = 8.3$ Hz, H-1), 8.11 (1H, s, H-12), 7.99 (1H, t, $J = 8.3$ Hz, H-2), 7.87 (1H, t, $J = 8.3$ Hz, H-3), 7.46–7.43 (2H, m, H-16, 20), 7.42–7.37 (3H, m, H-17, 18, 19), 5.37

(2H, s, H₂-14); (+)-HRESIMS m/z 412.1055 [M + Na]⁺ (calcd for C₂₅H₁₅N₃NaO₂, 412.1056).

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.5b02312.

¹H and ¹³C NMR spectra for 1, 3–5, and 13–27 and ¹H spectra of 11 and 28 (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: b.copp@auckland.ac.nz.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank the University of Auckland for funding this project.

■ REFERENCES

- Schmitz, F. J.; Agarwal, S. K.; Gunasekera, S. P.; Schmidt, P. G.; Shoolery, J. N. *J. Am. Chem. Soc.* **1983**, *105*, 4835–4836.
- Molinski, T. F. *Chem. Rev.* **1993**, *93*, 1825–1838.
- Skyler, D.; Heathcock, C. H. *J. Nat. Prod.* **2002**, *65*, 1573–1581.
- Marshall, K. M.; Barrows, L. R. *Nat. Prod. Rep.* **2004**, *21*, 731–751.
- de Guzman, F. S.; Carte, B.; Troupe, N.; Faulkner, D. J.; Harper, M. K.; Concepcion, G. P.; Mangalindan, G. C.; Matsumoto, S. S.; Barrows, L. R.; Ireland, C. M. *J. Org. Chem.* **1999**, *64*, 1400–1402.
- Tasdemir, D.; Marshall, K. M.; Mangalindan, G. C.; Concepcion, G. P.; Barrows, L. R.; Harper, M. K.; Ireland, C. M. *J. Org. Chem.* **2001**, *66*, 3246–3248.
- Bry, D.; Banaigs, B.; Long, C.; Bontemps, N. *Tetrahedron Lett.* **2011**, *52*, 3041–3044.
- Wei, X.; Bugni, T. S.; Harper, M. K.; Sandoval, I. T.; Manos, E. J.; Swift, J.; Van Wagoner, R. M.; Jones, D. A.; Ireland, C. M. *Mar. Drugs* **2010**, *8*, 1769–1778.
- Ponder, J.; Yoo, B. H.; Abraham, A. D.; Li, Q.; Ashley, A. K.; Amerin, C. L.; Zhou, Q.; Reid, B. G.; Reigan, P.; Hromas, R.; Nickoloff, J. A.; LaBarbera, D. V. *Mar. Drugs* **2011**, *9*, 2397–2408.
- Marshall, K. M.; Matsumoto, S. S.; Holden, J. A.; Concepcion, G. P.; Tasdemir, D.; Ireland, C. M.; Barrows, L. R. *Biochem. Pharmacol.* **2003**, *66*, 447–458.
- Marshall, K. M.; Andjelic, C. D.; Tasdemir, D.; Concepcion, G. P.; Ireland, C. M.; Barrows, L. R. *Mar. Drugs* **2009**, *7*, 196–209.
- Echavaren, A. M.; Stille, J. *J. Am. Chem. Soc.* **1988**, *110*, 4051–4053.
- Kubo, A.; Nakahara, S. *Heterocycles* **1988**, *27*, 2095–2098.
- Prager, R.; Tsopelas, C.; Heisler, T. *Aust. J. Chem.* **1991**, *44*, 277–285.
- Bracher, F.; Papke, T. *Liebigs Ann.* **1996**, *1996*, 115–116.
- Brahic, C.; Darro, F.; Belloir, M.; Bastide, J.; Kiss, R.; Delfourne, E. *Bioorg. Med. Chem.* **2002**, *10*, 2845–2853.
- Melzer, B.; Plodek, A.; Bracher, F. *J. Org. Chem.* **2014**, *79*, 7239–7272.
- Copp, B. R.; Jompa, J.; Tahir, A.; Ireland, C. M. *J. Org. Chem.* **1998**, *63*, 8024–8026.
- Skyler, D.; Heathcock, C. H. *Org. Lett.* **2001**, *3*, 4323–4324.
- Fong, H. K. H.; Copp, B. R. *Mar. Drugs* **2013**, *11*, 274–299.
- Newhouse, T.; Lewis, C. A.; Eastman, K. J.; Baran, P. S. *J. Am. Chem. Soc.* **2010**, *132*, 7119–7137.
- Kleijn, L. H.; Müskens, F. M.; Oppedijk, S. F.; de Bruin, G.; Martin, N. I. *Tetrahedron Lett.* **2012**, *53*, 6430–6432.
- Nemoto, H.; Nishiyama, T.; Akai, S. *Org. Lett.* **2011**, *13*, 2714–2717.

- (24) Lindsay, B. S.; Christiansen, H. C.; Copp, B. R. *Tetrahedron* **2000**, *56*, 497–505.
- (25) Thyagarajan, B. S. *Chem. Rev.* **1958**, *58*, 439–460.
- (26) Podrebarac, E. G.; McEwen, W. E. *J. Org. Chem.* **1961**, *26*, 1386–1389.
- (27) Matsumoto, S. S.; Biggs, J.; Copp, B. R.; Holden, J. A.; Barrows, L. R. *Chem. Res. Toxicol.* **2003**, *16*, 113–122.
- (28) Efforts to prepare **3** by direct methylation of **4** were unsuccessful, leading only to the production of polymeric/decomposition products.
- (29) Falck, B.; Hillarp, N. A.; Thieme, G.; Torp, A. *J. Histochem. Cytochem.* **1962**, *10*, 348–354.